Interim Position Statement: Interleukin-6 inhibitors (tocilizumab or sarilumab) for patients admitted to ICU with COVID-19 pneumonia (adults), MHRA (issued 8th January 2021)

The REMAP-CAP platform trial has reported survival and time to recovery benefits for tocilizumab or sarilumab. Clinicians should consider prescribing IV tocilizumab (sarilumab an alternative if available) following the criteria defined in this interim position statement.

Source: Current Awareness Service for Health (CASH) - January 11, 2021 Category: Consumer Health News Source Type: news